A methylome-based score to predict survival after regorafenib in recurrent glioblastoma

Lay Summary Glioblastoma is an aggressive brain cancer that often returns after treatment, and doctors need better ways to predict which patients will benefit from specific drugs. The authors of this study wanted to see whether patterns of chemical changes on tumor DNA could help predict how patients respond to a drug called regorafenib. To do this, they analyzed tumor samples from 33 patients with recurrent glioblastoma and compared these DNA patterns with how long patients lived and how long their disease stayed under control after treatment. They found that certain DNA patterns were linked to better responses to regorafenib, while specific genetic changes were associated with shorter survival, and they developed a DNA-based score that could help identify patients less likely to benefit from the drug.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Advances
Published
2026-04-27
DOI
https://doi.org/10.1093/noajnl/vdag108
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A methylome-based score to predict survival after regorafenib in recurrent glioblastoma

Ciro Mazzarella, Martina Offi, Simona Gaudino, Rosellina Russo et al.
Neuro-Oncology Advances
Glioma Diagnosis and Treatment
article

A methylome-based score to predict survival after regorafenib in recurrent glioblastoma

Ciro Mazzarella, Martina Offi, Simona Gaudino, Rosellina Russo, Giuliano Di Monaco, Maria Laura Falchetti, Silvia Chiesa, Flavia Vinciarelli, Lucia Ricci-Vitiani, Maria Antonietta Gambacorta, Evelina Miele, Antonella Martino, Lucia Pedace, Maurizio Martini, Angela Mastronuzzi, Marco Gessi, Roberto Pallini, Franco Locatelli, Quintino Giorgio D’Alessandris, Liverana Lauretti, Alessandro Olivi, Sara Patrizi
article en

Abstract

Lay Summary Glioblastoma is an aggressive brain cancer that often returns after treatment, and doctors need better ways to predict which patients will benefit from specific drugs. The authors of this study wanted to see whether patterns of chemical changes on tumor DNA could help predict how patients respond to a drug called regorafenib. To do this, they analyzed tumor samples from 33 patients with recurrent glioblastoma and compared these DNA patterns with how long patients lived and how long their disease stayed under control after treatment. They found that certain DNA patterns were linked to better responses to regorafenib, while specific genetic changes were associated with shorter survival, and they developed a DNA-based score that could help identify patients less likely to benefit from the drug.

Neuro-Oncology Advances
Università Cattolica del Sacro Cuore (IT), University of Messina (IT), Istituto Superiore di Sanità (IT), Agostino Gemelli University Polyclinic (IT), Gene Therapy Laboratory (FR), Bambino Gesù Children's Hospital (IT), Institute of Cell Biology and Neurobiology (IT)
Good health and well-being
Openalex Percentile: Top 7%
Glioma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.